AbbVie cuts 2026 EPS guidance to $13.91-$14.11 after $291 million Q2 IPR&D charge
AbbVie said its second-quarter 2026 results will include $291 million in pre-tax acquired IPR&D and milestones expense, which lowers both GAAP and adjusted diluted earnings per share by $0.17. The company cut its full-year 2026 adjusted EPS guidance to $13.91-$14.11 from $14.08-$14.28, so shareholders face lower expected earnings for the year. Second-quarter results have not been finalized and may differ from these preliminary figures.
- Q2 2026 acquired IPR&D and milestones expense of $291 million pre-tax, reducing GAAP and adjusted diluted EPS by $0.17
- Q2 2026 adjusted diluted EPS guidance now $3.57-$3.61, down from $3.74-$3.78
- Full-year 2026 adjusted diluted EPS guidance now $13.91-$14.11, down from the $14.08-$14.28 range announced April 29, 2026
- Quarter ended June 30, 2026 results are not final and could differ from the preliminary estimates